Developer docs
API playgroundTry for free, no card

Search company profiles

Knowledge Ecology International

Full company profile

uuid000ykh2

Namestring
Knowledge Ecology International
Legal namestring
Knowledge Ecology International
Websiteurl
keionline.org
Company typeenum
Private
Founded yearint
2006
Descriptiontext

Knowledge Ecology International (KEI) is a Washington, DC-based non-profit research and advocacy organization operating at the intersection of intellectual property, trade policy, and public health. Headquartered at 110 Maryland Avenue NE, Washington, DC 20002, with an operational presence in Geneva, Switzerland, KEI engages in policy research, legal analysis, and direct advocacy before multilateral bodies including the World Health Organization (WHO), World Intellectual Property Organization (WIPO), and World Trade Organization (WTO), as well as US government agencies such as NIH, FDA, USTR, and HHS.

KEI's core outputs are research publications, briefing notes, formal statements delivered at international proceedings, and publicly accessible databases including DrugDatabase.Info and the KEI Collection on the Internet Archive, which consolidate FOIA documents, patent licenses, government contracts, and historical timelines on IP and access-to-medicine debates. The organization does not develop commercial software or technology products; its underlying "platform" is its institutional knowledge, document repositories, and direct forum access enabled by formal accreditation as a non-state actor at WHO.

KEI operates as a non-profit funded through donations and grants from individuals and organizations supportive of its mission to promote access to knowledge and affordable medicines. Its go-to-market is event-driven advocacy: participating in WHO, WIPO, and WTO negotiations, hosting side events at major conferences, delivering statements on agenda items such as the Pandemic Agreement PABS Annex and WIPO Broadcast Treaty, and submitting comments on US government licensing decisions (e.g., NIH exclusive licenses to entities like OncoVanta). It serves institutional stakeholders (WHO member states, US agencies), coalition partners (Health Action International, Oxfam, World Blind Union, World Council of Churches, UAEM, Medicines Law & Policy, Innovarte), and the broader public health advocacy community.

Short descriptiontext

Knowledge Ecology International is a Washington, DC-based non-profit research and advocacy organization that conducts policy analysis and direct advocacy at the intersection of intellectual property, trade, and public health, engaging with WHO, WIPO, WTO, and US government agencies on access to medicines and related issues.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersWashington, United States
HQ citystring
Washington
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
policy advocacy services, intellectual property research, access to medicines, public health policy, nonprofit research organization
Industry3 codes
PRIMARYBPAGAFAO
Think Tanks, Policy Research & Public Policy Institutes
Business & Public Services/Nonprofit, NGO & Social Services/Civil Rights, Advocacy & Public Policy Organizations
SECONDARYBPAHALAF
Policy, Regulatory & Public Affairs Research
SECONDARYMPAJACAI
Government & Public Policy Publishing (Regulations, Gazettes, Legislative Tracking)
Media, Entertainment & Sports/Publishing (Books, News, Magazines)/Professional & Legal Publishing (Standards, Compliance, Reference)
NAICS code1 code
  • Web Search Portals, Libraries, Archives, and Other Information Services519
SIC code1 code
  • Services-Membership Organizations8600
Product category
Public Policy Advocacy and Research
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Donations and Grants
TypeProfessional Services
Description

KEI operates as a non-profit organization funded through donations and grants from individuals and organizations supportive of their mission to promote access to knowledge and medicine.

keionline.org
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components3 values
Personnel, Operations, Others
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

KEI conducts policy research, legal analysis, and advocacy at the intersection of intellectual property, trade, and public health. It delivers formal statements at WHO, WIPO, and WTO governing body meetings, publishes briefing notes and analysis, maintains public databases of FOIA documents and drug/patent information, and submits comments to US and international policymakers on issues including pandemic preparedness, compulsory licensing, technology transfer, and government patent licensing practices.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • KEI statements are regularly incorporated into WHO, WIPO, and WTO official records and negotiating texts
+1 more record
Product overview1 text field

Knowledge Ecology International (KEI) is a non-profit research and advocacy organization focused on knowledge ecology, intellectual property rights, access to medicines, and global health policy. The organization does not operate traditional commercial products or software services. Instead, KEI publishes research, briefing notes, databases (including DrugDatabase.Info and the KEI Collection on the Internet Archive), and provides policy advocacy and comments to international organizations including WHO, WIPO, WTO, and various government bodies.

Product and service6 records
1Policy Advocacy and Research Services
CategoryPolicy Advocacy
Description

Research, legal analysis, and direct advocacy delivered by KEI on the intersection of intellectual property, trade policy, and public health, aimed at policymakers and international organizations.

2Briefing Notes and Policy Publications
CategoryResearch Publications
Description

Freely available briefing notes, articles, and analytical papers (e.g., KEI Briefing Note 2026:4 on the WIPO Broadcast Treaty) covering WHO, WIPO, and WTO negotiating topics.

3DrugDatabase.Info
CategoryReference Database
Description

Public reference database on drugs, patents, and related policy information maintained by KEI to support access-to-medicines analysis.

4KEI Collection on the Internet Archive
CategoryReference Database
Description

Public archival collection of KEI's historical documents, FOIA releases, and policy materials hosted on the Internet Archive.

5Formal Statements and Interventions at International Bodies
CategoryPolicy Advocacy
Description

Official statements, interventions, and proposed negotiating text delivered by KEI at WHO, WIPO, and WTO governing body meetings (e.g., PABS Annex proposals, WHA 79 statements, CDIP opening statements).

6Government Agency Comments and Submissions
CategoryPolicy Advocacy
Description

Formal comments and submissions to US agencies such as NIH, FDA, USTR, and HHS on licensing proposals and policy matters (e.g., comments on the prospective OncoVanta exclusive patent license).

Scale indicator1 record

Each record includes

Type, Value, Description, Source

Partnership9 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2010-09-30
Description

The National Institutes of Health (NIH) granted a royalty-free nonexclusive license to the Medicines Patent Pool for patents on darunavir, an HIV protease inhibitor. KEI advocated for this license as a model for voluntary licensing of government-funded patents to improve access to affordable medicines in low- and middle-income countries.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

KEI is an accredited non-state actor at WHO, enabling participation in World Health Assemblies, Executive Board meetings, and negotiating bodies for pandemic agreements. They regularly deliver statements and participate in official sessions.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

KEI collaborates with Health Action International on joint constituency statements at WHO, including coordinated advocacy on the WHO Pandemic Accord negotiations.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

KEI partners with Oxfam on joint constituency statements and coordinated advocacy at WHO governing body meetings on pandemic preparedness and access to medicines.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

KEI collaborates with World Blind Union on joint constituency statements at WHO meetings, particularly on issues affecting access to health technologies.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

KEI partners with World Council of Churches on joint constituency statements at WHO governing body meetings.

7Universities Allied for Essential Medicines (UAEM)
Strategic tierMajorTypeStrategic or Co-development Partner
Description

KEI joined with UAEM and individual academics (Dr. Christopher Morten, Dr. Reshma Ramachandran) in submitting amicus briefs on FOIA and transparency matters, particularly regarding COVID-19 government contracts.

keionline.org
Strategic tierMajorTypeStrategic or Co-development Partner
Description

KEI co-convenes side events with Medicines Law & Policy at WHO headquarters on topics including technology transfer and pandemic preparedness.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

KEI co-organizes side events with Innovarte at WIPO on patent limitations and exceptions, including a 2024 event on best and worst practices for patent exceptions.

Recent move2 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

US-based activist and research organization focused on HIV, TB, and HCV treatment access. Comparable advocacy operating model and WHO-engagement footprint to KEI.

TypeDirect peer
Description

DC-based consumer and public-health advocacy organization that lobbies on access to medicines, drug pricing, and trade policy. Highly comparable to KEI in mission, geography, and use of regulatory comment processes at US agencies and Congress.

TypeBroad incumbent
Description

Large international NGO with a global access-to-medicines campaign that engages WHO and WTO. KEI is a formal coalition partner of Oxfam for joint constituency statements; broader scope but overlapping advocacy portfolio.

TypeDirect peer
Description

Amsterdam-based NGO that advocates for access to essential medicines and rational drug use. Direct peer: KEI lists HAI as a core coalition partner for joint WHO constituency statements.

TypeDirect peer
Description

Specialized advocacy and analysis organization on pharmaceutical IP law. Direct peer: KEI co-convenes WHO side events with ML&P on technology transfer and pandemic preparedness.

TypeBroad incumbent
Description

Large philanthropic foundation that funds access-to-medicines and public health advocacy work across multiple NGOs, including organizations in KEI's coalition network. Operates as an enabling funder/incumbent in the same policy space.

TypeEmerging player
Description

Non-profit R&D organization developing treatments for neglected diseases; while primarily a product developer rather than advocate, it operates in the same access-to-medicines ecosystem and engages WHO on IP and access frameworks.

TypeDirect peer
Description

International network of organizations working on trade, IP, and development issues, including access to medicines and WTO negotiations. Comparable focus on global-south perspectives in IP-health policy.

TypeDirect peer
Description

MSF's access-to-medicines advocacy arm engages directly with WHO, WIPO, and WTO on IP flexibilities, transparency, and pandemic preparedness. Closely comparable focus area and multilateral engagement profile to KEI.

10Universities Allied for Essential Medicines
TypeDirect peer
Description

Student-and-academic network advocating for access to medicines and equitable licensing of university-funded research. Direct peer: KEI has jointly filed amicus briefs with UAEM on COVID-19 government contract transparency.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Knowledge Ecology International

Public Policy Advocacy and Researchkeionline.org

Knowledge Ecology International is a Washington, DC-based non-profit research and advocacy organization that conducts policy analysis and direct advocacy at the intersection of intellectual property, trade, and public health, engaging with WHO, WIPO, WTO, and US government agencies on access to medicines and related issues.

What Knowledge Ecology International does

Knowledge Ecology International (KEI) is a Washington, DC-based non-profit research and advocacy organization operating at the intersection of intellectual property, trade policy, and public health. Headquartered at 110 Maryland Avenue NE, Washington, DC 20002, with an operational presence in Geneva, Switzerland, KEI engages in policy research, legal analysis, and direct advocacy before multilateral bodies including the World Health Organization (WHO), World Intellectual Property Organization (WIPO), and World Trade Organization (WTO), as well as US government agencies such as NIH, FDA, USTR, and HHS.

KEI's core outputs are research publications, briefing notes, formal statements delivered at international proceedings, and publicly accessible databases including DrugDatabase.Info and the KEI Collection on the Internet Archive, which consolidate FOIA documents, patent licenses, government contracts, and historical timelines on IP and access-to-medicine debates. The organization does not develop commercial software or technology products; its underlying "platform" is its institutional knowledge, document repositories, and direct forum access enabled by formal accreditation as a non-state actor at WHO.

KEI operates as a non-profit funded through donations and grants from individuals and organizations supportive of its mission to promote access to knowledge and affordable medicines. Its go-to-market is event-driven advocacy: participating in WHO, WIPO, and WTO negotiations, hosting side events at major conferences, delivering statements on agenda items such as the Pandemic Agreement PABS Annex and WIPO Broadcast Treaty, and submitting comments on US government licensing decisions (e.g., NIH exclusive licenses to entities like OncoVanta). It serves institutional stakeholders (WHO member states, US agencies), coalition partners (Health Action International, Oxfam, World Blind Union, World Council of Churches, UAEM, Medicines Law & Policy, Innovarte), and the broader public health advocacy community.

Knowledge Ecology International firmographics

Firmographics
Name
Knowledge Ecology International
Legal name
Knowledge Ecology International
Website
https://keionline.org
Company type
Private
Founded year
2006
Operating status
Operating
Headcount range
1–10 employees
Short description
Knowledge Ecology International is a Washington, DC-based non-profit research and advocacy organization that conducts policy analysis and direct advocacy at the intersection of intellectual property, trade, and public health, engaging with WHO, WIPO, WTO, and US government agencies on access to medicines and related issues.
Ownership category
akta.pro rank

Knowledge Ecology International industry classification

Industry
Product category
Public Policy Advocacy and Research
NAICS
Web Search Portals, Libraries, Archives, and Other Information Services (519)
SIC
Services-Membership Organizations (8600)
akta.pro industry
PRIMARYBPAGAFAO
Think Tanks, Policy Research & Public Policy Institutes
Business & Public Services/Nonprofit, NGO & Social Services/Civil Rights, Advocacy & Public Policy Organizations
SECONDARYBPAHALAF
Policy, Regulatory & Public Affairs Research
SECONDARYMPAJACAI
Government & Public Policy Publishing (Regulations, Gazettes, Legislative Tracking)
Media, Entertainment & Sports/Publishing (Books, News, Magazines)/Professional & Legal Publishing (Standards, Compliance, Reference)

Keywords

  • Policy advocacy services
  • Intellectual property research
  • Access to medicines
  • Public health policy
  • Nonprofit research organization

Where Knowledge Ecology International is headquartered

Location

Headquarters

HQ city
Washington
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Knowledge Ecology International business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Others

Revenue model

  1. Donations and Grants: KEI operates as a non-profit organization funded through donations and grants from individuals and organizations supportive of their mission to promote access to knowledge and medicine.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Knowledge Ecology International product offering

Product offering

Core offering

KEI conducts policy research, legal analysis, and advocacy at the intersection of intellectual property, trade, and public health. It delivers formal statements at WHO, WIPO, and WTO governing body meetings, publishes briefing notes and analysis, maintains public databases of FOIA documents and drug/patent information, and submits comments to US and international policymakers on issues including pandemic preparedness, compulsory licensing, technology transfer, and government patent licensing practices.

Product overview

Knowledge Ecology International (KEI) is a non-profit research and advocacy organization focused on knowledge ecology, intellectual property rights, access to medicines, and global health policy. The organization does not operate traditional commercial products or software services. Instead, KEI publishes research, briefing notes, databases (including DrugDatabase.Info and the KEI Collection on the Internet Archive), and provides policy advocacy and comments to international organizations including WHO, WIPO, WTO, and various government bodies.

Differentiator

Problem solved

Functional benefit

Products and services

  • Policy Advocacy and Research Services Research, legal analysis, and direct advocacy delivered by KEI on the intersection of intellectual property, trade policy, and public health, aimed at policymakers and international organizations.
  • Briefing Notes and Policy Publications Freely available briefing notes, articles, and analytical papers (e.g., KEI Briefing Note 2026:4 on the WIPO Broadcast Treaty) covering WHO, WIPO, and WTO negotiating topics.
  • DrugDatabase.Info Public reference database on drugs, patents, and related policy information maintained by KEI to support access-to-medicines analysis.
  • KEI Collection on the Internet Archive Public archival collection of KEI's historical documents, FOIA releases, and policy materials hosted on the Internet Archive.
  • Formal Statements and Interventions at International Bodies Official statements, interventions, and proposed negotiating text delivered by KEI at WHO, WIPO, and WTO governing body meetings (e.g., PABS Annex proposals, WHA 79 statements, CDIP opening statements).
  • Government Agency Comments and Submissions Formal comments and submissions to US agencies such as NIH, FDA, USTR, and HHS on licensing proposals and policy matters (e.g., comments on the prospective OncoVanta exclusive patent license).

Quantifiable outcome

  • KEI statements are regularly incorporated into WHO, WIPO, and WTO official records and negotiating texts
  • +1 more outcomes

Companies that use Knowledge Ecology International

Customer profile

Segments3 records

Ideal customer profiles3 records

Knowledge Ecology International technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Knowledge Ecology International partnerships and signals

Strategic signal

Partnerships

Nine partnerships are on record, tiered core, major and minor.

  • Medicines Patent Pool (MPP)coreStrategic or Co-development Partner · 30 September 2010The National Institutes of Health (NIH) granted a royalty-free nonexclusive license to the Medicines Patent Pool for patents on darunavir, an HIV protease inhibitor. KEI advocated for this license as a model for voluntary licensing of government-funded patents to improve access to affordable medicines in low- and middle-income countries.
  • World Health Organization (WHO)coreStrategic or Co-development PartnerKEI is an accredited non-state actor at WHO, enabling participation in World Health Assemblies, Executive Board meetings, and negotiating bodies for pandemic agreements. They regularly deliver statements and participate in official sessions.
  • Health Action InternationalcoreStrategic or Co-development PartnerKEI collaborates with Health Action International on joint constituency statements at WHO, including coordinated advocacy on the WHO Pandemic Accord negotiations.
  • OxfamcoreStrategic or Co-development PartnerKEI partners with Oxfam on joint constituency statements and coordinated advocacy at WHO governing body meetings on pandemic preparedness and access to medicines.
  • World Blind UnioncoreStrategic or Co-development PartnerKEI collaborates with World Blind Union on joint constituency statements at WHO meetings, particularly on issues affecting access to health technologies.
  • World Council of ChurchescoreStrategic or Co-development PartnerKEI partners with World Council of Churches on joint constituency statements at WHO governing body meetings.
  • Universities Allied for Essential Medicines (UAEM)majorStrategic or Co-development PartnerKEI joined with UAEM and individual academics (Dr. Christopher Morten, Dr. Reshma Ramachandran) in submitting amicus briefs on FOIA and transparency matters, particularly regarding COVID-19 government contracts.
  • Medicines Law & Policy (ML&P)majorStrategic or Co-development PartnerKEI co-convenes side events with Medicines Law & Policy at WHO headquarters on topics including technology transfer and pandemic preparedness.
  • InnovarteminorStrategic or Co-development PartnerKEI co-organizes side events with Innovarte at WIPO on patent limitations and exceptions, including a 2024 event on best and worst practices for patent exceptions.

Scale indicators1 record

Recent moves2 records

Expansion highlights5 records

Knowledge Ecology International competitors and assessment

Company assessment

Direct peers

  • Treatment Action Group: US-based activist and research organization focused on HIV, TB, and HCV treatment access. Comparable advocacy operating model and WHO-engagement footprint to KEI.
  • Public Citizen: DC-based consumer and public-health advocacy organization that lobbies on access to medicines, drug pricing, and trade policy. Highly comparable to KEI in mission, geography, and use of regulatory comment processes at US agencies and Congress.
  • Health Action International: Amsterdam-based NGO that advocates for access to essential medicines and rational drug use. Direct peer: KEI lists HAI as a core coalition partner for joint WHO constituency statements.
  • Medicines Law & Policy: Specialized advocacy and analysis organization on pharmaceutical IP law. Direct peer: KEI co-convenes WHO side events with ML&P on technology transfer and pandemic preparedness.
  • Third World Network: International network of organizations working on trade, IP, and development issues, including access to medicines and WTO negotiations. Comparable focus on global-south perspectives in IP-health policy.
  • Médecins Sans Frontières Access Campaign: MSF's access-to-medicines advocacy arm engages directly with WHO, WIPO, and WTO on IP flexibilities, transparency, and pandemic preparedness. Closely comparable focus area and multilateral engagement profile to KEI.
  • Universities Allied for Essential Medicines: Student-and-academic network advocating for access to medicines and equitable licensing of university-funded research. Direct peer: KEI has jointly filed amicus briefs with UAEM on COVID-19 government contract transparency.

Broad incumbents

  • Oxfam International: Large international NGO with a global access-to-medicines campaign that engages WHO and WTO. KEI is a formal coalition partner of Oxfam for joint constituency statements; broader scope but overlapping advocacy portfolio.
  • Open Society Foundations: Large philanthropic foundation that funds access-to-medicines and public health advocacy work across multiple NGOs, including organizations in KEI's coalition network. Operates as an enabling funder/incumbent in the same policy space.

Emerging players

  • Drugs for Neglected Diseases initiative: Non-profit R&D organization developing treatments for neglected diseases; while primarily a product developer rather than advocate, it operates in the same access-to-medicines ecosystem and engages WHO on IP and access frameworks.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Knowledge Ecology International social profiles

Digital presence

Knowledge Ecology International financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Knowledge Ecology International leadership team

Management profile

Number of profiles

Profiles3 records

Knowledge Ecology International funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Knowledge Ecology International M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Knowledge Ecology International

What does Knowledge Ecology International do?

KEI conducts policy research, legal analysis, and advocacy at the intersection of intellectual property, trade, and public health. It delivers formal statements at WHO, WIPO, and WTO governing body meetings, publishes briefing notes and analysis, maintains public databases of FOIA documents and drug/patent information, and submits comments to US and international policymakers on issues including pandemic preparedness, compulsory licensing, technology transfer, and government patent licensing practices.

Is Knowledge Ecology International a public or private company?

Knowledge Ecology International is a private company. It is classified as nonprofit foundation owned and is currently operating.

When was Knowledge Ecology International founded?

Knowledge Ecology International was founded in 2006. It employs 1 to 10 people.

Where is Knowledge Ecology International based?

Knowledge Ecology International is headquartered in Washington, United States, in the North America region.

How does Knowledge Ecology International make money?

One revenue line is on record: donations and Grants.

Who are Knowledge Ecology International's main competitors?

Direct peers on record are Treatment Action Group, Public Citizen, Health Action International, Medicines Law & Policy, Third World Network, Médecins Sans Frontières Access Campaign and Universities Allied for Essential Medicines. Broad incumbents are Oxfam International and Open Society Foundations. Drugs for Neglected Diseases initiative is listed as an emerging player.

Does Knowledge Ecology International have an API?

No public API is recorded for Knowledge Ecology International.

What industry is Knowledge Ecology International in?

Knowledge Ecology International's product category is Public Policy Advocacy and Research. Its primary akta.pro industry code is BPAGAFAO, Think Tanks, Policy Research & Public Policy Institutes, with a secondary code of BPAHALAF, Policy, Regulatory & Public Affairs Research. Its NAICS code is 519 and its SIC code is 8600.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Quiver QuantitativePress Release: Val Hoyle and Lloyd Doggett Reintroduce Bill to Lower Prescription Drug Prices | Stock NewsReps. Val Hoyle and Lloyd Doggett have reintroduced the Affordable Pricing for Taxpayer-Funded Prescription Drugs Act, which aims to lower drug costs by requiring affordable pricing agreements for medicines developed with federal funds. The bill also mandates manufacturers to disclose clinical trial costs and government subsidies. This proposal builds on the existing Inflation Reduction Act and has received endorsements from organizations like Public Citizen’s Access to Medicines Program and Knowledge Ecology International.Knowledge Ecology InternationalIGWG 7: KEI proposed text for a PABS AnnexKnowledge Ecology International (KEI) proposed specific text for a Pandemic Access and Benefit-Sharing (PABS) Annex during the Seventh meeting of the WHO Intergovernmental Working Group in Geneva. The proposal stipulates that manufacturers must provide evidence of a legally binding agreement with the WHO to register or sell pandemic-related products, linking market access to equity provisions rather than data sharing.Knowledge Ecology InternationalSubmission of Knowledge Ecology International on WIPO’s draft issues paper on Intellectual Property and Artificial IntelligenceKnowledge Ecology International (KEI) submitted comments on the World Intellectual Property Organization’s (WIPO) draft issues paper regarding intellectual property policy and artificial intelligence. The submission advocates for maintaining human-centric IP standards, arguing that AI-generated inventions and works should not be granted patents or copyrights without strict human oversight. KEI also warned against creating new data rights, citing potential anticompetitive practices and harm to innovation.Electronic Frontier FoundationLegislation to Reclaim University Invention from the TrollsEFF launched Reclaim Invention, urging universities to sign a pledge not to sell patents to patent assertion entities. Draft state legislation would require universities to adopt public-interest patent policies and void agreements with trolls. The project seeks to introduce the legislation in 50 states.BloombergLife-Saving Medicine, High Costs, and the Intractable Patent PuzzleNina Mahmud planned to fly to Washington, D.C., to question Bayer at a U.S. International Trade Commission hearing about its drug Nexavar. The drug costs her father-in-law about $115 daily in Egypt, while his monthly salary is under $300.CNETWikileaks publishes draft of secretive TPP trade pactWikileaks published a draft of the TPP's intellectual property chapter, the first public look at the secretive trade pact. The 95-page section covers digital rights, patents, and ISP liabilities, with critics warning it could limit Internet freedoms and expand corporate interests.Electronic Frontier FoundationHistoric Milestone for Rights of Readers as UN Negotiators Finalize Treaty for the BlindUN negotiators finalized a treaty on accessible books for the blind and print-disabled, after nearly a decade of drafting. Only 7% of published books are converted to accessible formats in rich countries, and the treaty legalizes cross-border sharing. It still needs ratification by member states.Ars TechnicaBlind advocates: Hollywood lobbying threatens deal for accessible booksLobbying by the MPAA and AAP is threatening the WIPO copyright treaty that would let blind people access books in accessible formats. The treaty's negotiations have stalled over provisions like the three-step test and a commercial availability requirement, which advocates say could block the deal.Ars TechnicaYour life will some day end; ACTA will live onLeaked ACTA text reveals a new institutional arrangements chapter, suggesting the agreement will create an international secretariat. The chapter aims to replace WTO and WIPO functions, bypassing their transparency and NGO participation rules.Ars TechnicaCanada, US pledge “transparency” on ACTAThe Obama administration met with civil society groups to discuss making ACTA negotiations more open, with suggestions to disclose all texts and agendas. USTR released a six-page document under new appointee Ron Kirk, citing the administration's commitment to transparency.